Chemotherapy-induced Nausea and Vomiting Drugs: Global Strategic Business Report

Quick Summary:

In the rapidly advancing realm of oncological treatments, the rising need for addressing the essential concerns of Chemotherapy-induced Nausea and Vomiting (CINV) cannot be understated. Detailed and data-driven research becomes critical to invest smartly in this prospective market. Our comprehensive global market report provides an in-depth analysis of the CINV Drugs market, offering a projected size of $4.6 billion by the year 2030 from an estimated $3.1 billion in 2022.

This report provides unparalleled insights into market trends and key segment growth, including the Serotonin Receptor Antagonist anticipated to reach $1.8 billion. Moreover, it presents an in-depth regional analysis, from the U.S. market, the world's largest economy valued at $922.7 Million, to fast-growing markets like China. Our market analysis is a vital instrument to successfully navigate the ever-competitive CINV pharmaceutical landscape. Select competitors' analysis provides a better understanding of the competition, thus enabling informed investment decisions.

The features that set our report apart include special coverage, global competitiveness, and market presence across multiple geographies, peer-to-peer online interactive updates, and access to digital archives and our research platform. Buy our CINV drugs market report today to capitalize on this booming industry.

Global Chemotherapy-induced Nausea and Vomiting Drugs Market to Reach $4.6 Billion by 2030

The global market for Chemotherapy-induced Nausea and Vomiting Drugs estimated at US$3.1 Billion in the year 2022, is projected to reach a revised size of US$4.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2022-2030. Serotonin Receptor Antagonist, one of the segments analyzed in the report, is projected to record 5.4% CAGR and reach US$1.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Neurokinin NK1 Receptor Antagonist segment is readjusted to a revised 5.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $922.7 Million, While China is Forecast to Grow at 4.9% CAGR

The Chemotherapy-induced Nausea and Vomiting Drugs market in the U.S. is estimated at US$922.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$809.8 Million by the year 2030 trailing a CAGR of 4.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 4.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Select Competitors (Total 23 Featured) -

Acacia Pharma Group Plc
Aphios Corporation
Baxter International Inc.
Dr. Reddy's Laboratories Ltd.
Eisai Co., Ltd.
Especificos Stendhal S.A. DE C.V.
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Helsinn Healthcare SA
Heron Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Lee's Pharmaceutical Holdings Ltd.
Merck & Co., Inc.
Midatech Pharma PLC
Mundipharma Pte., Ltd.
Mylan N.V.
Ono Pharmaceutical Co., Ltd.
Opko Health, Inc.
Orchid Chemicals & Pharmaceuticals Ltd
Otsuka Pharmaceutical Co., Ltd.
Purdue Pharma LP
Sandoz International GmbH
SciClone Pharmaceuticals, Inc.
Shin Nippon Biomedical Laboratories Ltd. (SNBL)
Solasia Pharma K.K.
Specialised Therapeutics Asia Pte Ltd
Sun Pharmaceutical Industries Ltd.
Taiho Pharmaceutical Co., Ltd.
Tesaro, Inc.
Teva Pharmaceutical Industries Ltd.

What's New?

Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to digital archives and Research Platform
Complimentary updates for one year

Frequently Asked Questions about the Global Market for Chemotherapy-induced Nausea and Vomiting Drugs

What is the estimated value of the Global Market for Chemotherapy-induced Nausea and Vomiting Drugs?

The Global Market for Chemotherapy-induced Nausea and Vomiting Drugs was estimated to be valued at $3.1 Billion in 2022.

What is the growth rate of the Global Market for Chemotherapy-induced Nausea and Vomiting Drugs?

The growth rate of the Global Market for Chemotherapy-induced Nausea and Vomiting Drugs is 5.1%, with an estimated value of $4.6 Billion by 2030.

What is the forecasted size of the Global Market for Chemotherapy-induced Nausea and Vomiting Drugs?

The Global Market for Chemotherapy-induced Nausea and Vomiting Drugs is estimated to be worth $4.6 Billion by 2030.

Who are the key companies in the Global Market for Chemotherapy-induced Nausea and Vomiting Drugs?

Key companies in the Global Market for Chemotherapy-induced Nausea and Vomiting Drugs include Acacia Pharma Group Plc, Aphios Corporation, Baxter International Inc., Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Especificos Stendhal S.A. DE C.V., F. Hoffmann, La Roche AG, GlaxoSmithKline PLC and Helsinn Healthcare SA.

Report Attribute	Details
No. of Pages	183
Published	October 2023
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 3.1 Billion
Forecasted Market Value ( USD ) by 2030	$ 4.6 Billion
Compound Annual Growth Rate	5.1%
Regions Covered	Global

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Chemotherapy-induced Nausea and Vomiting Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for Serotonin Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 5: World Historic Review for Serotonin Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 6: World 16-Year Perspective for Serotonin Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for Neurokinin NK1 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for Neurokinin NK1 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 9: World 16-Year Perspective for Neurokinin NK1 Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for Dopamine Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Dopamine Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 12: World 16-Year Perspective for Dopamine Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for Benzodiazepine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Benzodiazepine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 15: World 16-Year Perspective for Benzodiazepine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 18: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
Table 19: World Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES

Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
Table 20: USA Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 21: USA Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 22: USA 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

CANADA

Table 23: Canada Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 24: Canada Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 25: Canada 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

JAPAN

Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 26: Japan Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 27: Japan Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 28: Japan 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

CHINA

Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
Table 29: China Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 30: China Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 31: China 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

EUROPE

Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 32: Europe Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 33: Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 34: Europe 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
Table 35: Europe Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 36: Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 37: Europe 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

FRANCE

Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
Table 38: France Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 39: France Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 40: France 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

GERMANY

Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 41: Germany Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 42: Germany Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 43: Germany 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

ITALY

Table 44: Italy Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 45: Italy Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 46: Italy 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

UNITED KINGDOM

Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 47: UK Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 48: UK Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 49: UK 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

REST OF EUROPE

Table 50: Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 51: Rest of Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 52: Rest of Europe 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

ASIA-PACIFIC

Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 53: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 54: Asia-Pacific Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 55: Asia-Pacific 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

REST OF WORLD

Table 56: Rest of World Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 57: Rest of World Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 58: Rest of World 16-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2014, 2023 & 2030

IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

Acacia Pharma Group Plc
Aphios Corporation
Baxter International Inc.
Dr. Reddy's Laboratories Ltd.
Eisai Co., Ltd.
Especificos Stendhal S.A. DE C.V.
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Helsinn Healthcare SA
Heron Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Lee's Pharmaceutical Holdings Ltd.
Merck & Co., Inc.
Midatech Pharma PLC
Mundipharma Pte., Ltd.
Mylan N.V.
Ono Pharmaceutical Co., Ltd.
Opko Health, Inc.
Orchid Chemicals & Pharmaceuticals Ltd
Otsuka Pharmaceutical Co., Ltd.
Purdue Pharma LP
Sandoz International GmbH
SciClone Pharmaceuticals, Inc.
Shin Nippon Biomedical Laboratories Ltd. (SNBL)
Solasia Pharma K.K.
Specialised Therapeutics Asia Pte Ltd
Sun Pharmaceutical Industries Ltd.
Taiho Pharmaceutical Co., Ltd.
Tesaro, Inc.
Teva Pharmaceutical Industries Ltd.

Quick Summary:

Global Chemotherapy-induced Nausea and Vomiting Drugs Market to Reach $4.6 Billion by 2030

The U.S. Market is Estimated at $922.7 Million, While China is Forecast to Grow at 4.9% CAGR

Select Competitors (Total 23 Featured) -

What's New?

What is the estimated value of the Global Market for Chemotherapy-induced Nausea and Vomiting Drugs?

What is the growth rate of the Global Market for Chemotherapy-induced Nausea and Vomiting Drugs?

What is the forecasted size of the Global Market for Chemotherapy-induced Nausea and Vomiting Drugs?

Who are the key companies in the Global Market for Chemotherapy-induced Nausea and Vomiting Drugs?

Table of Contents

Companies Mentioned

Related Topics

Related Reports

Cancer Drugs Market, By Drug Class Type and By Indication By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Gastrointestinal Therapeutics Market Size, Share & Trends Analysis Report By Type, By Drug Class, By Application (Crohn's Disease, Ulcerative Colitis, GERD), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Antiemetics And Antinauseants Global Market Report 2023

Antiemetics Market By Drug Type, By Application, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type, By Drug Class, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030